Back to News
Market Impact: 0.28
Humacyte's Symvess Shelf Life Extended To 36 Months Following FDA Authorization
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
Humacyte said the FDA authorized extending Symvess's refrigerated shelf life to 36 months from 18 months. The doubling of the expiration period could improve inventory management, distribution flexibility, and commercial usability for the tissue-engineered vessel.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
HUMA0.62
More News
- Xencor reports phase 1 data for cancer drug XmAb819
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- Ukraine says Starlink and Starshield high speed restrictions have been lifted
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- How This County Made the Data Center Boom Pay Off